Female sexual interest drug reaches tipping point with Phase III plans
Pharmaceutical Technology
OCTOBER 10, 2022
Since the publication of the fifth Diagnostic and Statistical Manual of Mental Disorders in 2013, both conditions are grouped under the term FSIAD, which includes reduced arousal and interest. One Phase II trial was completed back in 2013, as per ClinicalTrials.gov. Neither Addyi nor Vyleesi is approved by the EMA.
Let's personalize your content